NuVasive, Inc.  

(Public, NASDAQ:NUVA)   Watch this stock  
Find more results for NUVA
+0.59 (0.77%)
After Hours: 73.25 -3.69 (-4.80%)
Apr 25, 6:48PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 76.62 - 77.87
52 week 51.13 - 77.88
Open 76.62
Vol / Avg. 0.00/489,678.00
Mkt cap 3.97B
P/E 112.27
Div/yield     -
EPS 0.69
Shares 50.66M
Beta 0.88
Inst. own 110%
Jul 24, 2017
Q2 2017 NuVasive Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 18, 2017
NuVasive Inc Annual Shareholders Meeting - 11:00AM EDT - Add to calendar
Apr 25, 2017
Q1 2017 NuVasive Inc Earnings Call - Webcast
Apr 25, 2017
Q1 2017 NuVasive Inc Earnings Release
Mar 14, 2017
NuVasive Inc at Barclays Global Healthcare Conference
Mar 7, 2017
NuVasive Inc at Cowen Health Care Conference
Feb 15, 2017
NuVasive Inc at Leerink Partners Global Healthcare Conference
Feb 9, 2017
Q4 2016 NuVasive Inc Earnings Call
Feb 9, 2017
Q4 2016 NuVasive Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 4.93% 3.68%
Operating margin 9.29% 12.84%
EBITD margin - 20.90%
Return on average assets 3.15% 2.47%
Return on average equity 7.38% 5.28%
Employees 2,200 -
CDP Score - -


7475 Lusk Blvd
SAN DIEGO, CA 92121-5707
United States - Map
+1-858-9091800 (Phone)
+1-800-4759134 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

Officers and directors

Gregory T. Lucier Chairman of the Board, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Jason M. Hannon President, Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew W. Link President - U.S. Commercial
Age: 42
Bio & Compensation  - Reuters
Patrick S. Miles Vice Chairman of the Board
Age: 51
Bio & Compensation  - Reuters
Quentin S. Blackford Chief Financial Officer, Executive Vice President Head of Strategy and Corporate Integrity
Age: 38
Bio & Compensation  - Reuters
Edmund J. Roschak Corporate Executive-NuVasive Specialized Orthopedics, Inc.
Age: 49
Bio & Compensation  - Reuters
Joan B. Stafslien Executive Vice President, General Counsel, Corporate Secretary
Age: 52
Bio & Compensation  - Reuters
Carol A. Cox Executive Vice President - External Affairs and Corporate Marketing
Age: 52
Bio & Compensation  - Reuters
Peter Michael Leddy Ph.D. Executive Vice President, Global Human Resources, Integrations, Real Estate and Internal Communications
Age: 53
Bio & Compensation  - Reuters
Vickie L. Capps Independent Director
Age: 55
Bio & Compensation  - Reuters